• DarioHealth reported a net loss of $8.25 million for the quarter ended March 31, 2026, narrowing 10.6%.
• Revenue dropped 17.3% to $5.58 million, primarily due to a non-recurring pharmaceutical partner revenue recognized in the prior-year period.
• Gross profit fell to $3.2 million, with gross margin easing 0.2 percentage points to 57.3% on higher hardware and consumables expenses.
• Research and development expense slid 41.9% to $2.39 million, while sales and marketing expense declined 16.6% to $4.9 million.
• Cash and cash equivalents totaled $14.98 million at March 31, 2026, and the company said current cash on hand is not expected to fund projected operating requirements for one year from issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DarioHealth Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-059676), on May 13, 2026, and is solely responsible for the information contained therein.